MOGAD has unique immune signature distinct from MS: Study
Multiple sclerosis (MS) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) share similar symptoms but are two biologically distinct conditions,…
Articles by Margarida Maia, PhD
Experimental MS therapy safely reaches brain in first human trial
SUDO-550, an oral TYK2 inhibitor being developed by Sudo Biosciences, was found to be safe, well-tolerated, and to fully…
ENHANCE trial testing simplified Briumvi dosing now fully enrolled
Enrollment is complete for the randomized part of ENHANCE, a large clinical trial testing a new dosing schedule for…
Obexelimab stops 95% of new MS brain lesions in trial
Obexelimab, a therapy Zenas Biopharma is developing for a range of autoimmune diseases, almost completely prevented the formation of…
1st MS patient dosed with Autolus’ CAR T-cell therapy in Phase 1 trial
The first patient has been dosed in a Phase 1 clinical trial of Autolus Therapeutics‘ experimental CAR T-cell therapy,…
Gene on X chromosome may fuel higher MS risk for women: Study
A gene on the X chromosome that is more active in women than men appears to drive inflammation in the…
Tr1x gets OK for first-in-human trial of TRX319 for progressive MS
The U.S. Food and Drug Administration (FDA) has given Tr1x the green light to launch a first-in-human clinical trial…
Researchers gain funds to advance a new type of treatment for MS
An international research team has secured nearly $800,000 (about CA$1.1 million) to advance a potential regenerative therapy for multiple…
FDA prioritizes Hope’s stem cell treatment with RMAT designation
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Hope Biosciences‘ adipose-derived…
New database aims to accelerate research into progressive MS
The International Progressive MS Alliance has introduced the MS Clinical and Imaging Data Resource, or CIDR, to accelerate the…
Copaxone reduces pediatric MS relapses by threefold versus Avonex
For children and adolescents with multiple sclerosis (MS), receiving treatment with Copaxone (glatiramer acetate) or its generic formulations…
Maintaining a healthy weight could cut MS risk, study finds
People genetically prone to a higher body mass index (BMI) are also more likely to develop multiple sclerosis (MS),…
Early signs of MS may appear years before a diagnosis
People who develop multiple sclerosis (MS) begin using healthcare services more frequently up to 15 years before their first…
Daily doses of Lucid-MS found safe in healthy adults in new study
Lucid-MS, an oral small-molecule being developed by Quantum Biopharma for treating multiple sclerosis (MS), was found to be…
Neurofilament light chain in blood, CSF may serve as MS biomarker
Neurofilament light chain (NfL) — a protein that gets released when nerve cells are damaged — is found at high…
Can estrogen hormones slow MS progression? Study says maybe yes.
In progressive forms of multiple sclerosis (MS), treatment with estrogen hormones such as estradiol may help reduce inflammation and nerve…
Comorbidities, insurance status drive emergency department visits
People with multiple sclerosis (MS) are significantly more likely to visit an emergency department if they have other health…
PAG-MS-guided exercise offers path to easing MS depression
Regular exercise that follows established guidelines for physical activity in multiple sclerosis (MS) leads to clinically meaningful gains in…
MS linked to increased healthcare use decades before diagnosis
People with multiple sclerosis (MS) visited doctors, were admitted to the hospital, and used emergency care more often than…
Transition from RRMS to SPMS fell in recent years; challenges remain
The rates of people with multiple sclerosis (MS) who advance from a relapsing disease course to a secondary progressive…
MIND diet plan strengthens antioxidant defenses in MS: Study
Following the MIND diet plan, rich in leafy greens, whole grains, legumes, nuts, berries, and lean meats, may help strengthen…
IMP761 dampens T-cell activity in healthy adults: Clinical study
In healthy adults, a single low dose of Immutep’s immunosuppressive candidate IMP761 continues to be safe and appears to…
Age at MS onset linked to long-term physical, mental health: Study
People who develop multiple sclerosis (MS) at a younger age tend to consistently have better physical health but worse…
Ambio’s ibogaine therapy program targets MS, other conditions
Ambio Life Sciences has launched a clinical program to test ibogaine — an experimental, naturally occurring psychedelic — for…
Phase 3 trials of vidofludimus calcium in relapsing MS enrolled
Enrollment is now complete in the twin Phase 3 clinical trials testing Immunic Therapeutics‘ oral small molecule vidofludimus…
BMI doesn’t affect response to stem cell transplant for MS
Body mass index (BMI), a measure commonly used measure of body fat based on a person’s height and weight, does…
Benefits of fenebrutinib in MS study sustained up to 2 years: Data
Almost two years of treatment with fenebrutinib — an investigational oral tablet for multiple sclerosis (MS) — helped…
Clinical tools can help detect early, subtle symptoms of MS: Study
While subtle symptoms of multiple sclerosis (MS) — like muscle weakness, fatigue, and numbness or unusual sensations — are…
MS patients in UK say they lack support to stay, thrive at work
Half of multiple sclerosis (MS) patients in the U.K. who work have compromised their health by staying in jobs…
Combined behavioral, cognitive training aids memory, coping skills
A 10-week program that combines cognitive behavioral therapy — a technique focused on understanding the connection between thoughts, feelings, and…